Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients

British Journal of Cancer

Volumn 76, Issue 2, 1997, Pages 211-219

  Jonsson, E ^a   Fridborg, H ^a   Csoka K ^a   Dhar, S ^a   Sundstrom C ^a   Nygren, P ^a   Larsson, R ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cytotoxicity assay; Drug resistance; Human tumour cell; Topotecan

Indexed keywords

ANTINEOPLASTIC ALKALOID; DNA TOPOISOMERASE (ATP HYDROLYSING); GLUTATHIONE; GLYCOPROTEIN P; TOPOTECAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; BREAST SARCOMA; CROSS RESISTANCE; CYTOTOXICITY TEST; DRUG CYTOTOXICITY; DRUG RESISTANCE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; SOLID TUMOR; TUMOR CELL CULTURE; TUMOR CELL LINE;

EID: 0030914996     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.364     Document Type: Article

References (47)

1. Ardizzoni A, Hansen H and Dombernowsky P (1994) Phase II study of topotecan in pretreated small cell lung cancer (SCLC). Proc Annu Meet Am Soc Clin Oncol 13: A1116
2. Botling J, Liminga G, Larsson R, Nygren P and Nilsson K (1994) Development of vincristine resistance and increased sensitivity to cyclosporin A and verapamil in the human U-937 lymphoma cell line without overexpression of the 170 kDa p-glycoprotein. Int J Cancer 58: 269-274
3. Boyd M and Paull K (1995) Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen, Drug Develop Res 34: 91-109
4. Burris H, Hanauske A, Johnsson R, Marshall M, Kuhn J, Hilsenbeck SG and von Hoff D (1992) Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst 84: 1816-1819
5. Chang A, Garrow G, Boros L, Asbury R, Pandya K and Keng P (1995) Clinical and laboratory studies of topotecan in breast cancer. Proc Anna Meet Am Soc Clin Oncol 14: A118
6. Cheng M, Chatterjee S and Merger N (1994) Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. Oncol Res 6: 269-279
7. Cole S, Bhardwaj G, Gerlach J, Mackie J, Grant C, Almquist K, Stewan A, Kurz E, Duncan A and Deeley R (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650-1654
8. Cordell J, Falini B and Erber W (1984) Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 32: 219-229
9. Csoka K, Larsson R, Tholander B, Gerdin E, De La Torre M and Nygren P (1994) Cytotoxic drug sensitiviy testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Gynecol Oncol 54: 163-170
10. Csoka K, Liliemark J, Larsson R and Nygren P (1995) Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors. Semin Oncol 22: 47-53
11. Dalton W, Durie B, Alberts D, Gerlach J and Cress A (1986) Characterization of a new drug-resistant human myeloma cell line that expresses p-glycoprotein. Cancer Res 46: 5125-5130
12. Dancey J and Eisenhauer E (1996) Current perspectives on camptothecins in cancer treatment. Br J Cancel 74: 327-338
13. Danks M, Schmidt C, Cirtain M, Suttle D and Beck W (1988) Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry 27: 8861-8869
14. Dhar S, Nygren P, Csoka K, Botling J, Nilsson K and Larsson R (1996) Anticancer drug characterization using human cell line panel representing defined types of drug resistance. Br J Cancer 74: 888-896
15. Eisenhauer E. Wainman N, Boos G, Macdonald D and Bramwell V (1994) Phase II trials of topotecan in patients (pis) with malignant glioma and soft tissue sarcoma. Proc Annu Meet Am Soc Clin Oncol 13: A488
16. Eng W, McCabe F. Tan K, Mattern M, Holmann G, Woessner R, Hertzberg R and Johnsson R (1990) Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Mol Pharmacol 38: 471-480
17. Friedman H, Houghton P, Schold S, Keir S and Bigner D (1994) Activity of 9-dimethylaminomethylcamptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 34: 171-174
18. Gore M, Bolis B, Creemers G, Despax R, Guastalla J, Lacave J, Mee D, Scarfone G, ten Bokkel Huinink W and van Belle S (1996) A phase II study of topotecan as second-line therapy given as five daily doses for advanced epithelial ovarian cancer. 9th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, A474.
19. Hendricks C, Rowinsky H, Grochow I., Donchower R and Kaufmann S (1992) Effect of p-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res 52: 2268-2278
20. Holm C, Covey J, Kerrigan D and Pommier Y (1989) Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and 11 inhibitors in Chinese hamster DC3F cells. Cancer Res 49: 6365-6368
21. Koughton P, Cheshire P, Myers L, Stewart C, Synold T and Houghton J (1992) Evaluation of 9-dimethylanminomelhyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol 31: 229-239
22. Houghton P, Cheshire P, Hallman J, Lutz L, Friedman H, Danks M and Houghton J (1995) Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 36: 393-403
23. Ilson D, Motzer R, O'Moore P, Nanus D and Bosl G (1993) A phase II trial of topotecan in advanced renal cell carcinoma. Proc Annu Meet Am Soc Clin Oncol 12: A779
24. Jonsson B, Liminga G, Csoka K, Fridborg H, Dhar S, Nygren P and Larsson R (1996) Cytotoxic activity of Calcein acetoxymethyl ester (Calcein/AM) on primary cultures of human haematological and solid tumours. Eur J Cancer 32A: 883-887
25. Kantarjian H, Beran M, Ellis A, Zwelling L, O'Brien S, Cazenave L, Koller C, Rios M, Plunkett W, Keating W and Estey E (1993) Phase I study of topotecan, a new topoisomerase inhibitor, in patients with refractory or relapsed acute leukemia. Blood 81: 1146-1151
26. Karlsson M, Molnar V, Bergh J, Freijs A and Larsson R (1996) A general model for time-dissociated PK/PD relationships. Manuscript.
27. Larsson R, Kristensen J, Sandberg C and Nygren P (1992) Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia using a fluorometric microculture cytotoxicity assay (FMCA) Int J Cancer 50: 177-185
28. Larsson R, Fridborg H, Liliemark J, Csoka K, Kristensen J, de la Torre M and Nygren P (1994) In vitro activity of 2-chlorodeoxyadenosine (CdA) in primary cultures of human haematological and solid tumours. Eur. J Cancer 30A: 1022-1026
29. Law T, Ilson D and Motzer R (1994) Phase II trial of topotecan in patients with advanced renal cell carcinoma, Invest New Drugs 12: 143-145
30. Mattern M, Hofmann G, Polsky R, Funk L, McCabe F and Johnson R (1993) In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells. Oncol Res 5: 467-474
31. Mulcahy R, Bailey H and Gipp J (1994) Up-regulation of gamma-glutamylcysteine synthetase activity in melphalan-resistant human multiple myeloma cells expressing increased glutathione levels. Cancer Chemother Pharmacol 34: 67-71
32. 2+ concentration, Biosci Rep 10: 231-237
33. Nygren P. Kristensen J, Sundström C, Lönnerholm G, Kreuger A and Larsson R (1992) feasibility of the fluoromctric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphoblastic leukemia. Leukemia 11: 1121-1128
34. Nygren P, Fridborg H, Csoka K, Sundström C, De La Torre M, Kristensen J, Bergh J, Hagberg H, Glimelius B, Rastad J, Tholander B and Larsson R (1994) Detection of tumor-specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. InI J Cancer 56: 715-720
35. Nygren P, Csoka K, Jonsson B, Fridborg H, Bergh J, Hagberg H, Glimelius B, Brodin O, Tholander B, Kreuger A, Lönnerholm G, Jakobsson Å, Olsen L, Kristenssen J and Larsson R (1995) The cytotoxic activity of Taxol in primary cultures of tumor cells from patients is partly mediated by Cremophor EL, Br J Cancer 71: 478-481
36. Percz-Soler R, Fossella F, Glisson B, Lee J, Murphy W, Shin D, Kemp B, Lee J, Kane J, Robinson R, Lippman S, Kurie J, Huber M, Raber M and Hong W (1996) Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol 14: 503-513
37. Rowinsky E, Adjei A, Donehower R, Gore S, Jones R, Burke P, Cheng Y, Grochow L and Kaufmann S (1994) Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J Clin Oncol 12: 2193-2203
38. Shiller J, Kim K and Johnson D (1994) Phase II study of topotecan in extensive stage small cell lung cancer. Proc Annu Meet Am Soc Clin Oncol 13: A330
39. Sliutz G, Karlseder J, Tempter C, Orel L, Holzer G and Simon M (1996) Drug resistance against gemcitabine and topotecan mediated by constitutive hsp70 overexpression in vitro: implication of quercetin as sensitiser in chemotherapy. Br J Cancer 74: 172-177
40. Sorensen M, Sehested M and Jensen P (1995) Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan. Br J Cancer 72: 399-404
41. Sugarman S, Ajani J, Daugherty K, Winn R, Lanzotti V, Bearden J and Abbruzzese J (1994) A phase M trial of topoteean (TPT) for the treatment of advanced, measurable colorectal cancer. Proc Annu Meet Am Soc Clin Oncol 13: A686
42. Takimoto C and Arhuck S (1996) The camptothecins. In Cancer Chemotherapy and Biotherapy-Principles and Practice, Chabner B and Longo D (eds). p. 463. Lippincott: Philadelphia
43. Tan K, Mattern M, Eng W, McCabe F and Johnson R (1989) Nonproductive rearrangement of DNA topoisomerase I and II genes; correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst 81: 1732-1735
44. Uckun F, Stewart G, Reaman G, Chelstrom L, Jin J, Chandan-Langlie M, Waddick K, White J and Evans W (1995) In vitro and in vivo activity of topotecan against human B-lineuge acute lymphoblastic leukemia cells. Blood 85: 2817-2828
45. Verovski V, Van den Berge D, Delvaeye M, Scheper R, De Neve W and Storme G (1996) Low-level doxorubicin resistance in P-glycoprotein negative human pancreatic tumor PSN1/ADR cells implicates a brefeldin A-sensitive mechanism of drug extrusion. Br J Cancer 73: 596-602
46. Wall J, Burris H, Von Hoff D, Rodriguez G, Kneuper-Hall R, Shatter D, O'Rourke T, Brown T, Weiss G, Clark G, McVea S, Brown J, Johnson R, Friedman C, Smith B, Mann W and Kuhn J (1992) A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anti-Cancer Drugs 3: 337-345
47. Yang C, Horion J, Cowan K and Schneider E (1995) Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. Cancer Res 55: 4004-4009